Briefings
Readout previews and analyses of the design-graded trial record. Every date, grade and figure on these pages renders live from the database.
Where the weak phase 3s are9.8% of the phase-3 trials graded on this site cannot isolate the effect of the drug by design. This briefing shows what those trials have in common and where they cluster.2026-10-08Q4 2026 readouts that matterFive phase-3 primary completions the registry currently schedules for the fourth quarter, read through the evidence each program already carries.2026-08-25